Mithradote Bio

Mithradote Bio is a San Diego-based biotechnology company founded by Sophia Lee in 2023. The firm is focused on developing products to protect individuals from drug-facilitated sexual assault.

The company's lead product is M-101, a novel, self-administered sublingual strip designed to act as a pan-antidote against common drink-spiking drugs like benzodiazepines (such as Rohypnol) and other GABA agonists. This convenient oral film medication is designed for rapid absorption and drug neutralization, providing a fast-acting solution for individuals who suspect they have been drugged.

In October 2024, Mithradote Bio secured $1 million in an oversubscribed seed funding round. The round was co-led by Taho Pharma and Vickers Venture Partners and is intended to advance the development of M-101 and initiate another pipeline program. The company has also established strategic development agreements with Haorui Pharmatech for API manufacturing and Taho Pharma for the oral delivery formulation, leveraging Taho's expertise in oral film medications.

Keywords: drug-facilitated sexual assault, drink spiking antidote, sublingual strip, M-101, biotechnology, biopharmaceutical, benzodiazepine antidote, GABA agonists, date-rape drug solution, personal safety, rapid drug neutralization, oral film medication